UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report: March 16, 2016

 

 

CYRUSONE INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

1649 West Frankford Road

Carrollton, TX 75007

(Address of Principal Executive Office)

 

Registrant’s telephone number, including area code: (972) 350-0060

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o                 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o                 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o                 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o                 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

ITEM 8.01 — OTHER EVENTS

 

On March 16, 2016, CyrusOne Inc. (“CyrusOne”) issued a press release announcing that it has priced a public offering of 6,000,000 shares of its common stock at a price to the public of $38.50 per share.  The offering was upsized from the previously announced public offering of 5,500,000 shares of common stock.  The underwriters have been granted an option to purchase up to 900,000 additional shares of common stock from CyrusOne at the public offering price, less underwriting discounts.

 

CyrusOne will contribute, directly and indirectly, the net proceeds from the offering to its operating partnership, CyrusOne LP (the “Operating Partnership”), in exchange for 6,000,000 newly issued common units  (or 6,900,000 common units if the underwriters exercise their option to purchase additional shares of CyrusOne’s common stock in full) of limited partnership interests in the Operating Partnership.

 

The Operating Partnership is expected to use such proceeds to finance, in part, its previously announced acquisition (the “Acquisition”) of certain property in Aurora, Illinois from CME Group Inc., to pay fees and expenses related to the Acquisition, to fund capital expenditures related to recently signed leases, to repay outstanding indebtedness under its revolving credit facility and for general corporate purposes. In the event the Operating Partnership does not consummate the Acquisition, it is expected to use such proceeds to fund capital expenditures related to recently signed leases, to repay outstanding indebtedness under its revolving credit facility and for general corporate purposes.

 

A copy of the press release is furnished herewith as Exhibit 99.1.

 

ITEM 9.01 — FINANCIAL STATEMENTS AND EXHIBITS

 

(d) Exhibits

 

Exhibit No.		Description
99.1		Press Release dated March 16, 2016.

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

	CYRUSONE INC.
Date: March 16, 2016	By:	/s/ Robert M. Jackson
		Robert M. Jackson
		Executive Vice President, General Counsel and Secretary

 

3

 

EXHIBIT INDEX

 

Exhibit No.		Description
99.1		Press Release dated March 16, 2016.

 

4